 |
Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine
Apr 17, 2012
|
15.0 KB |
|
| |
BERKELEY HEIGHTS, N.J., April 17, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP); (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Patent an...
|
|
Personalized Medicine and Combination Potential of Cyclacel's Sapacitabine Highlighted at AACR
Apr 4, 2012
|
18.9 KB |
|
| |
BERKELEY HEIGHTS, N.J., April 4, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP); (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today the presentation of thre...
|
|
Cyclacel's Novel Polo-Like Kinase 1 (Plk1) Inhibitors Highlighted at AACR
Apr 2, 2012
|
17.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., April 2, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today the presentation of trans...
|
|
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 29, 2012
|
30.0 KB |
|
| |
BERKELEY HEIGHTS, N.J., March 29, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today its financial results and business highlights for the fourth quarter and full year 2011. The Company's net loss applicable to common stockholders for the fourth quarter of 2011 was $3.8...
|
|
Cyclacel to Announce Year-End and Fourth Quarter 2011 Financial Results and Multiple Presentations at the Upcoming AACR Conference
Mar 26, 2012
|
15.7 KB |
|
| |
BERKELEY HEIGHTS, N.J., March 26, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced upcoming corporate events.Year End and Fourth Quarter 2011 Financial Results — Thursday, March 29, 2012
Cyclacel will announce year-end and fourth quarter 2011 financial resul...
|
|
Cyclacel Announces $3.0 Million Financing to Fund Ongoing Litigation Expenses on Certain Intellectual Property
Mar 22, 2012
|
13.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., March 22, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced that the Company entered into a purchase agreement with certain existing institutional stockholders raising $3,036,000 in gross proceeds. The proceeds from the financing will be used t...
|
|
Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes
Feb 13, 2012
|
17.6 KB |
|
| |
BERKELEY HEIGHTS, N.J., Feb. 13, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today new topline response data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes...
|
|
Cyclacel to Present at Upcoming Investor Conferences
Feb 6, 2012
|
13.2 KB |
|
| |
BERKELEY HEIGHTS, N.J., Feb. 6, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that Spiro Rombotis, President and Chief Executive Officer, will present an update on the Company's programs at two upcoming conferences in New York.14th Annual BIO CEO & Investor Confere...
|
|
Cyclacel Provides Corporate Update at OneMedForum Conference
Jan 11, 2012
|
22.6 KB |
|
| |
BERKELEY HEIGHTS, N.J., Jan. 11, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today summarized its 2011 achievements and set forth the Company's key business objectives for 2012 in a presentation given by Spiro Rombotis, President and Chief Executive Officer, at the 5th Annual On...
|
|
Cyclacel to Present at the 5th Annual OneMedForum in San Francisco
Jan 6, 2012
|
12.9 KB |
|
| |
BERKELEY HEIGHTS, N.J., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced that Spiro Rombotis, President and Chief Executive Officer, will review the Company's 2011 achievements and key clinical development and business objectives for 2012 at the 5th Annual ...
|
|
Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML
Dec 12, 2011
|
18.9 KB |
|
| |
BERKELEY HEIGHTS, N.J., Dec. 12, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP); (Cyclacel or the Company), announced today updated results from an ongoing, multicenter, Phase 1/2 clinical trial examining the safety and efficacy of oral sapacitabine, the Company's lead product candidate, administered sequential...
|
|
Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients
Dec 7, 2011
|
21.4 KB |
|
| |
- Partial responses and stable disease observed in patients with lung cancer and also in patients with breast, pancreatic and ovarian cancer carrying BRCA mutations -
- Sapacitabine unique among nucleoside analogues because of its oral dosing and broad therapeutic window of activity in both solid tumors and hematological malignancies -
BERK...
|
|
Cyclacel to Webcast Analyst & Institutional Investor Meeting Wednesday, December 7, 2011
Dec 1, 2011
|
14.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., Dec. 1, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), will host an Analyst and Institutional Investor meeting on December 7, 2011 in New York City from 11:00 a.m. to 1:00 p.m. Eastern. During the meeting Cyclacel management will review the clinical development...
|
|
Cyclacel Pharmaceuticals Reports Third Quarter 2011 Financial Results
Nov 14, 2011
|
30.0 KB |
|
| |
SEAMLESS Phase 3 trial design simplified; FDA confirmed that SPA remains valid Conference Call Scheduled November 14, 2011 at 4:30 p.m. Eastern Time
BERKELEY HEIGHTS, N.J., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today its financial results and business ...
|
|
Cyclacel to Announce Third Quarter 2011 Financial Results and Upcoming Corporate Events
Nov 7, 2011
|
15.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., Nov. 7, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced certain corporate events that will take place during November and December 2011.Release of 3Q11 Financial Results and Conference Call — Monday, November 14
Cyclacel will announce its thi...
|
|
Cyclacel to Present at BIO Investor Forum
Oct 19, 2011
|
12.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., Oct. 19, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today that Spiro Rombotis, President and Chief Executive Officer, will present at the 10th Annual BIO Investor Forum in San Francisco, California. Cyclacel's presentation will take place on Wedne...
|
|
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine
Oct 13, 2011
|
17.1 KB |
|
| |
BERKELEY HEIGHTS, N.J., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the independent Data Safe...
|
|
Cyclacel Receives Deficiency Notice from NASDAQ Global Select Market
Sep 22, 2011
|
13.4 KB |
|
| |
Berkeley Heights, NJ, September 22,
2011 – Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel
or the Company), today announced that it received a Nasdaq Staff
Deficiency Letter on September 16, 2011 indicating that the Company
fails to comply with the minimum bid price requirement for
continued listing set f...
|
|
Cyclacel announces commencement of investigator-initiated phase 2 trial of sapacitabine in patients with CLL or SLL hematological malignancies and 11q22-23 deletion
Aug 30, 2011
|
17.5 KB |
|
| |
Berkeley Heights, NJ, August 30, 2011 –
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel or the Company), today announced that the first patient
has been dosed in an investigator-initiated, translational, Phase 2
clinical study at The University of Texas MD Anderson Cancer
Center. The objective of...
|
|
Cyclacel reports second quarter 2011 financial results
Aug 11, 2011
|
19.7 KB |
|
| |
Berkeley Heights, NJ,
August 11, 2011 – Cyclacel Pharmaceuticals, Inc.
(NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), announced
today its financial results and business highlights for the second
quarter of 2011.
The Company’s net loss applicable to common stockho...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter